Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 291 of 5804
-
New Light-Activated gel could save diabetic feet from amputation
Disease control Recruiting nowProtocol No. CHLORIN E6-IIB/III-01/Protocol/1.1 Title:Single-Centre, open-labeled, randomized, Phase IIb and Phase III clinical studies to evaluate the safety, tolerability, and efficacy of Chlorin E6 (Gel Formation) as a photosensitizing agent for the management of Diabetic Foot…
Phase: PHASE3 • Sponsor: United Medical and Dental College • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New vaccine aims to shield african infants from two deadly infections
⭐️ VACCINE ⭐️ Recruiting nowThe purpose of this study is to evaluate the safety, reactogenicity, and immune response induced by the GlaxoSmithKline Biologicals SA (GSK) Vaccines Institute for Global Health (GVGH) invasive nontyphoidal Salmonella-typhoid conjugate (iNTS-TCV) vaccine in infants with the first…
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:10 UTC
-
New hope for STK11 lung cancer: experimental combo enters trial
Disease control Recruiting nowThis phase II trial tests how well GT103 in combination with pembrolizumab works in treating patients with STK11 mutant non-small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has s…
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug IBI3003 enters first human trials for Hard-to-Treat multiple myeloma
Disease control Not yet recruitingThis is a phase 1/2 multicenter, open-label, first-in-human study of IBI3003. It includes a phase 1 dose escalation and expansion section to identify maximum tolerated dose(MTD)/recommended Phase 2 Dose(RP2D) of IBI3003, plans to enroll 54\~360 subjects, and a phase 2 stage to ex…
Phase: PHASE1, PHASE2 • Sponsor: Fortvita Biologics (USA)Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New hope for hard-to-treat breast cancer: experimental drug SYS6010 enters final testing phase
Disease control Not yet recruitingThis study is a multicenter, randomized, open-label, parallel-control Phase III clinical trial enrolling patients with unresectable HER2-negative, EGFR-positive recurrent/metastatic breast cancer who have previously failed first- or second-line chemotherapy. It aims to compare th…
Phase: PHASE3 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Could a gut bug boost Crohn's treatment? new trial investigates
Disease control Not yet recruitingThis study aims to evaluate whether the combination of Akkermansia muciniphila with infliximab can improve intestinal mucosal healing in patients with Crohn's disease compared with infliximab alone.
Phase: PHASE4 • Sponsor: Chinese Medical Association • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New Triple-Drug hair loss treatment enters final testing phase
Disease control Recruiting nowThe goal of this clinical trial is to learn whether a new topical solution, TH07, can help treat androgenic alopecia in men and to learn more about its safety. Participants will be asked to apply either the TH07 solution, a standard hair growth treatment (Minoxidil 5%), or a plac…
Phase: PHASE3 • Sponsor: Triple Hair Inc • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New study tests best Follow-Up after surgery for oral cancer
Disease control Not yet recruitingNeoadjuvant immunochemotherapy (NAIC) has demonstrated promising pathological and survival outcomes in patients with resectable locally advanced oral and oropharyngeal squamous cell carcinoma (LA-OSCC/OPSCC). However, the optimal postoperative management strategy following NAIC a…
Sponsor: Zhujiang Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug combo aims to tame rare artery disease
Disease control Not yet recruitingThis is a prospective, open-label, controlled, multiple centers, randonmized clinical trial. It compares the clinical efficacy and safety of vunakizumab ivarmacitinib and glucocorticoids in the treatment of active Takayasu's arteritis.
Phase: PHASE4 • Sponsor: Chinese SLE Treatment And Research Group • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New hope for Wake-Up stroke patients: drug may boost recovery
Disease control Not yet recruitingThe benefit of intravenous tenecteplase for acute ischemic stroke with unknown time of onset, e.g. wake-up stroke, remains uncertain. This randomized study aims to assess the efficacy and safety of intravenous tenecteplase following non-contrast CT screening for acute ischemic st…
Phase: PHASE3 • Sponsor: First Affiliated Hospital of Guangxi Medical University • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Could a simple injection stop pancreatic leaks after surgery?
Prevention Not yet recruitingThis study is a randomized, double-blind, placebo-controlled, multicenter phase III clinical trial designed to evaluate the efficacy and safety of octreotide microspheres in preventing pancreatic fistula after distal pancreatectomy.
Phase: PHASE3 • Sponsor: Shanghai Zhongshan Hospital • Aim: Prevention
Last updated Jun 27, 2026 11:03 UTC
-
Timing is everything: new trial aims to save lives from immune storm
Disease control Not yet recruitingHemophagocytic lymphohistiocytosis (HLH) is an immune-mediated disorder characterized by hyperactivation of the immune system, leading to a cytokine storm responsible for organ failures. Consequently, patients with HLH often require intensive care management, where their short-te…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo therapy aims to save kidneys in High-Risk cancer patients
Disease control Not yet recruitingUTUC is a cancer that develops in the lining of the kidney or ureter. The standard treatment is radical nephroureterectomy, which removes the kidney and ureter. Although this surgery can control the cancer, it permanently reduces kidney function. Endoscopic treatment can serve a…
Sponsor: Peking University First Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo therapy aims to control early lung cancer without surgery
Disease control Not yet recruitingThe goal of this Single-arm, Phase II clinical trial is to learn whether ablation or stereotactic radiotherapy combined with furmonertinib can treat early-stage non-small cell lung cancer in patients who are inoperable or refuse surgery. The main purposes of this study is to ans…
Phase: PHASE2 • Sponsor: Shanghai Pulmonary Hospital, Shanghai, China • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Could a blood thinner and heart pill prevent deadly liver complications?
Disease control Recruiting nowThe APIXABAN-PK trial is a prospective, randomized, single-blind, placebo-controlled study designed to evaluate the efficacy and safety of apixaban in combination with carvedilol versus placebo with carvedilol in preventing portal hypertension-related complications in patients wi…
Phase: PHASE4 • Sponsor: Asian Institute Of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New hope for tough breast cancer: targeted drug HLX43 enters phase 2 trial
Disease control Not yet recruitingThis is a Phase II Study of HLX43 in Hormone Receptor Positive,HER-2 negative Locally Advanced or Metastatic Breast Cancer Patients with Disease Progression on Standard of Care. Eligible subjects will be treated with the study drug until the loss of clinical benefit, death, intol…
Phase: PHASE2 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Stroke drug trial aims to boost brain recovery after clot removal
Disease control Not yet recruitingThe goal of this clinical trial is to learn if immediate intra-arterial tirofiban after complete recanalization can improve recovery in adults with acute ischemic stroke caused by anterior circulation large-vessel occlusion. It will also learn about the safety of this treatment. …
Phase: PHASE3 • Sponsor: Shandong Provincial Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could stem cell exosomes recolor white patches in vitiligo?
Disease control Not yet recruitingThis study evaluates whether exosomes derived from human umbilical cord mesenchymal stem cells (hUMSCs-Exo) are safe and effective for treating vitiligo in adults. Vitiligo is a skin condition that causes white patches due to loss of pigment-producing cells. Current treatments h…
Phase: PHASE1, PHASE2 • Sponsor: Xijing Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Could a blood pressure cuff help fight septic shock?
Disease control Not yet recruitingSeptic shock is a leading cause of death worldwide despite intensive research efforts. Only a few interventions have been proven to be effective in improving patient-centered outcomes. Recent clinical trials have reported the safety and efficacy of remote ischemic postconditionin…
Phase: NA • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug duo aims to shrink oral cancers before surgery
Disease control Not yet recruitingThe purpose of this study is to evaluate the effectiveness and safety of the combination therapy of Becotatug Vedotin with Pucotenlimab as a possible neoadjuvant therapyand for locally advanced oral/pharyngeal squamous cell carcinoma.
Phase: PHASE2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC